Related Experiment Video
Updated: Mar 3, 2026
Ex Vivo Corneal Organ Culture Model for Wound Healing Studies
Published on: February 15, 2019
Beyond Organ-Specific Therapies: A Unified Approach to Multi-Organ Fibrosis
Ziyan Pan1, Shadi Zerehpoosh1, Shu-Chi Wang2,3,4,5
1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia.
Abstract:
Organ fibrosis, characterized by excessive scarring of tissues in the liver, kidney, lung, and heart, poses a significant and growing global health challenge, resulting in considerable morbidity and mortality, with a lack of effective treatment options. Most research and drug development efforts have traditionally focused on individual organs in isolation. This review aims to provide a comprehensive perspective on multi-organ fibrosis, highlighting recent advances that clarify the complex cellular and molecular mechanisms involved in the liver, kidney, lung, and heart. It examines both common and organ-specific factors that drive fibrogenesis. Additionally, the review discusses the current and future landscape of antifibrotic therapies, including innovative approaches to developing pan-organ antifibrotic drugs. Challenges and future directions in the design of clinical trials are also addressed.
Insights
Organ fibrosis, affecting multiple organs like the liver, kidney, lung, and heart, is a major health issue. This review explores common and specific fibrotic mechanisms and discusses new pan-organ antifibrotic drug strategies.
Area of Science:
- Fibrosis research
- Multi-organ pathology
- Drug development
Background:
- Organ fibrosis, excessive tissue scarring in liver, kidney, lung, and heart, presents a significant global health challenge with high morbidity and mortality.
- Current research and therapeutic strategies often focus on individual organs, limiting comprehensive treatment approaches.
- A lack of effective antifibrotic treatments necessitates a broader understanding of fibrogenesis.
Purpose of the Study:
- To provide a comprehensive review of multi-organ fibrosis, integrating insights from liver, kidney, lung, and heart.
- To elucidate the complex cellular and molecular mechanisms underlying fibrogenesis across different organs.
- To explore current and future antifibrotic therapies, including novel pan-organ drug development.
Main Methods:
- Literature review of recent advances in organ fibrosis research.
- Analysis of common and organ-specific factors driving fibrogenesis.
- Examination of existing and emerging antifibrotic therapeutic strategies.
Main Results:
- Recent advances have clarified complex cellular and molecular mechanisms in liver, kidney, lung, and heart fibrosis.
- Both shared and distinct fibrotic drivers exist across different organs.
- Innovative approaches for pan-organ antifibrotic drug development are emerging.
Conclusions:
- Understanding multi-organ fibrosis requires a holistic approach, considering shared and unique mechanisms.
- Developing pan-organ antifibrotic therapies holds promise for treating widespread fibrotic diseases.
- Future clinical trial designs must address the complexities of multi-organ fibrotic conditions.
